Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2001;89:389-400
doi: 10.1161/hh1701.096259
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Isner, J. M.
Right arrow Articles by Losordo, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isner, J. M.
Right arrow Articles by Losordo, D. W.
Related Collections
Right arrow Restenosis
Right arrow Angiogenesis
Right arrow Other arteriosclerosis
(Circulation Research. 2001;89:389.)
© 2001 American Heart Association, Inc.


Reviews

Assessment of Risks Associated With Cardiovascular Gene Therapy in Human Subjects

Jeffrey M. Isner, Peter R. Vale, James F. Symes, Douglas W. Losordo

From the Shaughnessy Center for Clinical Genetics, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Mass.

Correspondence to Jeffrey M. Isner, MD, St. Elizabeth’s Medical Center, 736 Cambridge St, Boston, MA 02493. E-mail VeJeff{at}aol.com

Abstract

Clinical trials of cardiovascular gene therapy, whether using viral (53%) or nonviral (47%) vectors, have thus far disclosed no evidence indicative of inflammatory or other complications, including death, directly attributable to the vector used. Indeed, despite the fact that initial trials of cardiovascular gene therapy targeted patients with end-stage vascular disease, including critical limb ischemia and refractory myocardial ischemia, the mortality for patients enrolled in clinical trials of cardiovascular gene therapy reported to date compares favorably with mortality for similar groups of patients in contemporary controlled studies of medical or interventional therapies. The most common morbidity reported after cardiovascular gene transfer is lower extremity edema; in contrast to data involving genetically engineered mice, however, evidence of life- or limb-threatening edema has not been described in any patients, including patients after gene transfer for myocardial ischemia. Concerns regarding the potential for angiogenic cytokines to promote the progression of atherosclerosis are not supported by angiographic follow-up of patients with coronary or peripheral vascular disease. The levels and duration of gene expression investigated for therapeutic angiogenesis transfer have been unassociated with hemangioma formation. Likewise, there is little evidence from either preclinical or clinical studies to support the notion that the administration of angiogenic growth factors, per se, is sufficient to stimulate the growth of neoplasms. Patients enrolled in clinical studies of angiogenic cytokines, including patients with diabetes and a previous history of retinopathy, have disclosed no evidence to suggest that ocular pathology is a risk of angiogenic growth factor gene transfer.


Key Words: gene therapy • coronary artery disease • peripheral vascular disease




This article has been cited by other articles:


Home page
Circ. Res.Home page
R. Gupta, J. Tongers, and D. W. Losordo
Human Studies of Angiogenic Gene Therapy
Circ. Res., October 9, 2009; 105(8): 724 - 736.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. C.M. Siow and A. T. Churchman
Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in
Cardiovasc Res, September 1, 2007; 75(4): 659 - 668.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
H. Ly, Y. Kawase, R. Yoneyama, and R. J. Hajjar
Gene Therapy in the Treatment of Heart Failure
Physiology, April 1, 2007; 22(2): 81 - 96.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Susen, K. Sautiere, F. Mouquet, F. Cuilleret, A. Chmait, E. P. McFadden, B. Hennache, F. Richard, P. de Groote, J.-M. Lablanche, et al.
Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization
Eur. Heart J., November 2, 2005; 26(22): 2387 - 2395.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Imada, T. Tatsumi, Y. Mori, T. Nishiue, M. Yoshida, H. Masaki, M. Okigaki, H. Kojima, Y. Nozawa, Y. Nishiwaki, et al.
Targeted Delivery of Bone Marrow Mononuclear Cells by Ultrasound Destruction of Microbubbles Induces Both Angiogenesis and Arteriogenesis Response
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2128 - 2134.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Y. Izumi, S. Kim-Mitsuyama, M. Yoshiyama, T. Omura, M. Shiota, A. Matsuzawa, T. Yukimura, T. Murohara, M. Takeya, H. Ichijo, et al.
Important Role of Apoptosis Signal-Regulating Kinase 1 in Ischemia-Induced Angiogenesis
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1877 - 1883.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
Y. Watanabe and D. D. Heistad
Targeting cerebral arteries for gene therapy
Exp Physiol, May 1, 2005; 90(3): 327 - 331.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Errico, T. Riccioni, S. Iyer, C. Pisano, K. R. Acharya, M. G. Persico, and S. De Falco
Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 Receptor
J. Biol. Chem., October 15, 2004; 279(42): 43929 - 43939.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C.L Grines
The AGENT clinical trials programme
Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E18 - E23.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Hattan, D. Warltier, W. Gu, C. Kolz, W. M. Chilian, and D. Weihrauch
Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H488 - H493.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Omori, K. Naruishi, F. Nishimura, H. Yamada-Naruishi, and S. Takashiba
High Glucose Enhances Interleukin-6-induced Vascular Endothelial Growth Factor 165 Expression via Activation of Gp130-mediated p44/42 MAPK-CCAAT/Enhancer Binding Protein Signaling in Gingival Fibroblasts
J. Biol. Chem., February 20, 2004; 279(8): 6643 - 6649.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
C. A.U. Heilmann, T. Attmann, A. Thiem, E. Haffner, F. Beyersdorf, and G. Lutter
Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia
Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 785 - 793.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
E. R Mohler III, S. Rajagopalan, J. W Olin, J. D Trachtenberg, H. Rasmussen, R. Pak, and R. G Crystal
Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial
Vascular Medicine, February 1, 2003; 8(1): 9 - 13.
[Abstract] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
C. A.U. Heilmann, T. Attmann, P. von Samson, H. Gobel, D. Marme, F. Beyersdorf, and G. Lutter
Transmyocardial laser revascularization combined with vascular endothelial growth factor121 (VEGF121) gene therapy for chronic myocardial ischemia - do the effects really add up?
Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 74 - 80.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini
Biological activities of fibroblast growth factor-2 in the adult myocardium
Cardiovasc Res, January 1, 2003; 57(1): 8 - 19.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. G. Bliznakov, C. L. Grines, R. Engler, J. Brinker, J. Rade, G. Helmer, J. Marmur, W. Penny, M. W. Watkins, P. Marrott, et al.
Therapeutic Angiogenesis: Hope or Hype * Response
Circulation, December 17, 2002; 106 (25): e220 - e221.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
C. Heilmann, P. von Samson, K. Schlegel, T. Attmann, B.-U. von Specht, F. Beyersdorf, and G. Lutter
Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2
Eur. J. Cardiothorac. Surg., December 1, 2002; 22(6): 957 - 964.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O. Iba, H. Matsubara, Y. Nozawa, S. Fujiyama, K. Amano, Y. Mori, H. Kojima, and T. Iwasaka
Angiogenesis by Implantation of Peripheral Blood Mononuclear Cells and Platelets Into Ischemic Limbs
Circulation, October 8, 2002; 106(15): 2019 - 2025.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. C. LaPointe, X.-P. Yang, O. A. Carretero, and Q. He
Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector
Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1439 - H1445.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Pislaru, S. P. Janssens, B. J. Gersh, and R. D. Simari
Defining Gene Transfer Before Expecting Gene Therapy: Putting the Horse Before the Cart
Circulation, July 30, 2002; 106(5): 631 - 636.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
P Menasche and M Desnos
Cardiac reparation: fixing the heart with cells, new vessels and genes
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D73 - D81.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. Burkhoff
Invited commentary
Ann. Thorac. Surg., March 1, 2002; 73(3): 824 - 824.
[Full Text] [PDF]